This document discusses FLT3-ITD mutations in acute myeloid leukemia (AML) and the use of FLT3 tyrosine kinase inhibitors (TKIs) in the setting of allogeneic stem cell transplantation for AML. FLT3-ITD mutations occur in around 25% of AML cases and are associated with an inferior prognosis. TKIs like sorafenib and quizartinib have shown efficacy in relapsed/refractory FLT3-ITD positive AML, particularly after allogeneic stem cell transplantation. Ongoing clinical trials are investigating the use of TKIs as maintenance therapy before and after transplantation to improve outcomes for AML patients with FLT